Using a Health Savings Account for Retirement Funds? Avoid These 3 Mistakes

Key numbers: 2026 HSA eligibility requires a high-deductible health plan with deductibles ≥ $1,700 (individual) or ≥ $3,400 (family); 2026 contribution limits are $4,400 for individuals and $8,750 for families, with a $1,000 catch-up for those 55+. Practical guidance: investors should invest HSA balances to boost long-term retirement savings, avoid using HSA funds for current medical bills if targeting retirement use, and beware tax penalties for ineligible or excess contributions.

Analysis

Shifting household behavior toward treating HSAs as retirement vehicles is a slow-moving structural flow into custody and asset-management lines rather than into health providers. Even a mid-single-digit percentage shift of existing HSA balances from cash into equities would raise recurring fee income materially for niche custodians; at a 1% blended fee, every $1B of AUM is roughly $10m of recurring revenue that compounds and is less cyclically tied to claims.

The substitution away from using HSAs for current medical bills creates two second-order market moves: (1) demand for short-term medical credit and BNPL plans will be lower, pressuring players that monetize point-of-care lending; (2) product innovation around HSA-to-taxable-rollover, auto-invest rules and low-cost ETF wrappers will accelerate, concentrating flows to platforms that integrate custody + investing. Expect product winners to be the firms that can cross-sell IRA/401(k)-like investing functionality into HSA balances within 12–36 months.

Regulatory and macro risks are the main reversers. A tightening of eligibility or contribution rules, meaningful fee regulation, or a sharp equity drawdown (>20% S&P correction) would halt conversion to invested HSAs and force outflows back into cash; any of those could compress multiples on custodians quickly. Conversely, if rates stay elevated, the opportunity cost of investing these balances rises and adoption will be slower — so time your exposure to custodians to the path of equities vs. short-term rates over the next 6–18 months.

Key Decisions for Investors

• Long HQY (HealthEquity) — allocate 0.5–1.0% NAV, target +25–35% in 9–12 months as AUM/fee growth materializes; set a soft stop at -20% or hedge with a 12-month protective put sized to limit drawdown to -15%.
• Long SCHW (Charles Schwab) — 0.5–1.0% NAV, 12-month horizon to capture incremental brokerage flows as retail/broad-market HSA investing migrates to major brokers; upside 15–25% if custody share expands, downside -15% on fee compression or rate-driven cash preference.
• Directional call spread on NVDA to express marginal equity inflows into large-cap tech via HSA allocations — buy a Jan-2027 call spread sized 0.25–0.5% NAV (debit), aim for 3x+ payoff if mega-cap rotation continues; max loss = premium paid, catalyst window 6–18 months.
• Risk hedge: buy a 12-month protective put on HQY (or collar the HQY position) sized 0.5% NAV to cap downside to ~15% in the event of regulatory action or a >15% equity drawdown — pay the premium as insurance given concentrated regulatory tail risk.